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Abstract
Many biomarker-based diagnostics have poor predictive value because of their dependence on
naturally occurring endogenous biomolecules to indicate disease. This work presents a diagnostic
platform that uses nanoparticles to profile underlying proteolytic signatures of diseases. In this
thesis, work is presented on long circulating peptide-nanoparticle probes that can survey, sense,
and remotely report on dysregulated protease activities in cancer. In this strategy, iron oxide
nanoparticles are utilized as chaperones to deliver protease-specific peptide libraries to tumors
whereupon selective cleavage by active proteases releases peptide fragments that are cleared by
the renal system into the urine. These peptide fragments are predesigned with internal
photolabile triggers that uncage isobaric peptide mass tags optimized for multiplexed LC MS/MS
quantification. Results demonstrate that such peptide 'synthetic biomarker' panels uncover
unique proteolytic signatures that can be correlated with disease states, allowing for the detection
of cancer and potential long-term monitoring of disease using an implantable form. This concept
of administering prodiagnostic reagents and analyzing remote reporters is amenable to a broad
range of protease-dependent complex diseases, such as liver fibrosis and coagulopathies, and
infectious disease.
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Chapter 1
Introduction
1.1 Biomarkers in Disease
One of the major goals associated with noninvasive diagnostics of complex diseases is
the development of sensitive and specific biomarker assays for early detection and monitoring
(1,2). Biomarkers serve as important measurable indicators of physiological states, particularly
signifying the presence or stage of a disease. Various forms of biomarkers have demonstrated
much potential for screening, diagnosing, and monitoring diseases in addition to guiding
personalized therapies and assessing the efficacy of therapies (9). Biomarkers that have been
identified and validated for use, include circulating tumor cells (3), proteins (2,4), peptides (5),
metabolites (2), cell-free DNA and RNA (2,6), microRNAs (7), and exosomes (8). Enzymatic
activities have also been used as biomarkers to predict disease. Alkaline and acid phosphatase
activities were used successfully to predict the presence of bone disease and prostate cancer [4],
respectively. Enzymes such as these were attractive options for biomarkers because of the high
sensitivity associated with detecting their cleaved products.
Biomarkers have been successfully discovered for a variety of diseases, but many
problems are associated with accurately detecting them. Renal diseases, such as acute renal
failure, have been targeted for biomarker discovery because of their lack of characterization,
difficulty to be diagnosed early, and their preferred diagnostic method being the biopsy, a highly
invasive procedure. Similar issues have prompted the need for liver disease biomarkers as well
and so studies have focused on finding direct markers for liver fibrogenesis that release into the
peripheral blood, including various proteins such as cytokines and enzymes (collagenases and
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metalloproteinases) (28). Additionally, proteomic approaches have been applied for analysis of
biomarkers for lung, breast, ovarian, colon, and prostate cancers for early detection and
monitoring (2). However, there remains significant challenges with naturally occurring
biomarkers, including the inability to detect early stage disease, making more invasive diagnostic
procedures, such as biopsies, necessary. The development of diagnostics that incorporate
effective combinations of biomarkers with improved sensitivity and specificity will be needed to
circumvent the current problems with biomarker tests.
1.2 Detecting Biomarkers
The ability of blood biomarkers to dynamically reflect multiple disease states and its
relative ease of collection from patients have made blood central to many diagnostic assays (4).
For most serum analytes, robust detection in plasma is challenging since most biomarkers are
shed from diseases tissues at low levels and are further diluted upon entering systemic
circulation. If the average primary tumor size is ~0.05mL then biomolecules shed into the blood,
which has a total volume of ~5L, will be diluted by a factor of 105. Further, these signals of
interest can easily become masked by the complexity of the plasma proteome, which contains
hundreds of proteins present at high concentrations such as Albumin (4). Biomolecules can also
be degraded in vivo and ex vivo.
Mass spectrometry has emerged as a technology for analyzing protein and peptide
biomarkers, but is especially hindered by the inability to sensitively detect low signal due to
complex samples. While these limitations can only be overcome by extensive sample processing,
fractionation, chromatography, and data analysis, which is costly and time consuming (9),
alternative biological fluids, particularly urine, offer a proteomically simpler and non-invasive
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source for detecting disease (9, 10). However, urine has drawbacks including a molecular weight
cut-off (<60kDa) (9,11), which would inhibit the detection of enzymes and other informative
biomarkers released from the disease site. While in some cases of kidney disease and cancer
larger biomarkers, including proteins, are released into the urine and become detectable (11), this
is generally not amenable to a broad range of diseases.
Many of the challenges associated with blood and urine diagnostics could be overcome by
the administration of exogenous biomarkers. Exogenous agents have been designed to report on
the underlying physiology of specific diseases, such as activity-based probes that fit into active
sites within proteases and report on their activity in vivo (12,13). Other examples of exogenous
diagnostics are molecules for imaging, such as FDG-PET, for determining sites of glucose
metabolism. Challenges with these approaches, however, include the inability to multiplex
signals (limitations with reporter output such as fluorophore spectral overlap) and other
difficulties that are associated with specifically delivering the diagnostic to the disease site and
avoiding rapid renal clearance.
1.3 Proteases in Disease
Proteases are essential for the control of many biological processes and for the function
of most biological systems across all living organisms. Within this role, proteases have been
found to activate many proteins, regulate protein-protein interactions, interact within cellular
pathways of processing information, and create and amplify molecular signals (14). These
functions translate to influencing DNA replication/transcription, angiogenesis, wound repair,
stem cell movement, blood clotting, immunity, inflammation, activation of zymogens,
remodeling of the extracellular matrix (ECM), and apoptosis (14). Because of all these roles,
aberrant protease activity is related to a variety of diseases, including cancer, neurodegenerative
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disorders, inflammatory conditions, and cardiovascular diseases. A positive correlation between
MMP expression and tumor progression has been found as MMPs play an active role in tumor
invasion and metastasis by degrading the ECM and in basement membrane turnover for invasion
of cancerous cells into the underlying organs and vasculature (29). Chronic obstructive
pulmonary disease and emphysema have been shown to be caused by destruction of the alveoli
by excessive neutrophil elastase activity. Hepatic fibrosis can also be caused by aberrant elastase
activity and matrix degradation caused by metalloproteinases. When the balance of proteases and
their inhibitors is tipped, architectural elements and function of the liver are drastically altered.
Dysregulated proteases play a role in the progression of a variety of diseases and are an attractive
target for developing a diagnostic platform.
1.4 Detection of Proteases
The nature of proteases to act on a variety of substrates and their role in health and
disease makes them amenable for real-time, non-invasive monitoring for diagnosing disease.
Because of the promiscuity of proteases for endogenous substrate degradation, multiplexed
quantification of protease activity would elucidate protease network interactions into abnormal
biological states. Activity-based probes have been developed in multiple studies for analyzing
protease activity. When these probes bind to the active size of the enzymes of interest, they
covalently bind. Because they are labeled with fluorophores or biotin, they allow for
visualization or affinity purification of the active enzymes, respectively. This approach has been
adopted for labeling numerous biomedically relevant enzymes, including serine hydrolases,
cysteine proteases, and oxidoreductases (12). Additionally, probes have been designed to study
the MMPs in live cells and in animals for the purpose of identifying MMPs upregulated in cancer
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cells and for aiding in the development of inhibitors for clinical use. Near-infrared florescent
molecular probes have also been developed for detecting MMP, cathepsin, and caspase activity
through live imaging in tumor-bearing animals (30).
A major issue with most of these probing mechanisms is that there is much promiscuity
between enzymes and their substrates. As many of these detection methods, including
zymography, mass-spectrometry based systems, and activity based probes, do not simultaneously
allow for non-invasiveness, specificity, and high throughput, new approaches are being tested,
such as the 'Proteolytic Activity Matrix Analysis' (PrAMA) method. This method addressed
many of these issues by using FRET-substrates for dynamic, multiplexed quantification of
specific protease activities. Through using previously determined cleavage patterns of substrates
by the purified enzymes, PrAMA deconvolutes specific protease activity from complex protease
signatures. PrAMA has been validated for identifying protease activity within complex networks
in vitro with a strong potential for systems biology to screening inhibitors (31). This is an
important advancement because current fluorogenic approaches do not provide the same level of
specificity and multiplexing abilities.
Fluorescent-based approaches are highly limited by spectral overlap and thus do not
allow for simultaneous measurement of multiple enzyme activities while mass spectrometry has
many advantages because it allows for a broad range of masses to be detected accurately and
thus providing multiplexed reporters. Quantitative approaches involving mass spectrometry for
tracking multiple cleavage events would improve the accuracy of current diagnostics and perhaps
broaden the range of diseases that could be detected with a set of probes.
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1.5 Quantitative Mass Spectrometry for Detecting Protease Activity
Using insight attained from quantitative MS, protease detection assays with multiplexed
capabilities could be developed. Because of the pressing need to characterize the proteome for
analyses of biological systems and pathways, quantitative MS technologies have been developed.
Approaches for proteome analysis usually begin with two-dimensional gel electrophoresis and
selected proteins are further analyzed with quantitative MS or tandem MS/MS (57-61). Issues
associated with these traditional methods for proteome quantification include the labor,
sensitivity issues, and the masking of less abundant proteins. A technique for the general labeling
of proteins and their quantified detection by MS has been developed using isotope-coded affinity
tags (ICAT) (62) (Fig. 1-1). ICAT reagents contain a specific chemistry group for the reaction of
interest, which in this study, was a thiol reactive group for cysteine modification. They further
consist of a linker, which is isotope encoded, and an affinity tagged. The isotope-encoding
scheme involves heavy (eight deuteriums) and light forms (no deuteriums) of the linker, allowing
for quantification of duplexed peaks of the same protein from different samples (Fig. 1-2). After
the ratio of proteins from different cell states are calculated from the relative peak heights in the
MS, fragmentation of these peaks in the MS/MS enables the identification of the proteins,
allowing for a complete picture to be obtained of the protein expression differences between two
cells or states.
Further development of isotope-encoding using isobaric rags has resulted in greater
multiplexing with isobaric tags for relative and absolute quantitation (iTRAQ) (32, 63).
Currently, iTRAQ allows for 4-plex (Fig. 1-3) and 8-plex experiments in measuring proteins.
Because iTRAQ uses isobaric tags, proteins are only differentiated by fragmentation peaks that
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vary by 1 mass unit in the MS/MS. The iTRAQ reagents are balanced such that before
fragmentation all the variants are of equal mass, meaning that a protein from different samples
will display as a single parent peak in the MS. Only upon fragmentation are the reporter ions,
which differ by one mass unit, exposed (Fig. 1-4). Isobaric approaches offer more multiplexing
ability and greater sensitivity than other approaches. However, the isobaric technologies
developed so far have leveled out at a maximum of 8 different tags (64), which is limiting for a
widespread proteome analysis of cells or in vivo disease signatures. Because mass spectrometry
has much promise in highly multiplexed, quantitative, analyses of biological systems, adapting
isobaric techniques using peptide standards that ionize efficiently and yield high signal is
desired. By using peptides for isotopic-encoding, more probes can be generated than is
achievable with small molecule tags, allowing for a more multiplexed analyses to be performed
for measuring proteases in vivo.
Heavy reagent: d8-ICAT (X = deuterium)
Light reagent: d0-ICAT (X = hydrogen)
O NH 0 X X 0
HN N 0 O0 N
H H XX X H
Biotin tag Linker (heavy or light) Thiol reactive
group
Figure 1-1: iCAT reagent used for labeling proteins with an isotope-encoded tag that allows for
quantification of protein signatures by tandem mass spectrometry between two cell states. Reproduced
from (62).
17
too,
I0
Retention im
[dentify proteins by sequence information (MS/MS scan)
too EA -ICAT ei
NHI-.EACDIPL~ecoomi -* Peptide A dafines Protein A
oIW Lo
Massich0rg0
0
Figure 1-2: The tandem mass spectrometry scheme for quantifying iCAT labeled proteins. Proteins
between two cell states are first measured by MS parent peaks and displayed as two peaks separated by a
few mass units. After fragmentation, the quantified protein peaks can be identified using the
fragmentation spectrum in MS/MS. Reproduced from (62).
Isoberic Tag
Total mass = 145
Amine specif pepWe
Reporter Group mass reactIve group (NHS)
114 -117 (Retains Charge)
N N
N O
Balance Group
Mass 31-28 (Neutral loss)
N PEPTIDE
N O
m/Z 114 (+1) 13C '3C 60 (+3)
mz 15 (+2) 13C2  '80 (+2)
nVz 116 (+3) 13C2 15N 13C (
mlz 117 (+4) "C3 IN (+0)
Figure 1-3: The iTRAQ reagent used for labeling proteins with isobaric mass tags. The scheme for
developing a 4-plex reagent set is shown. The reagent is balanced around the carbonyl bond such that all
four variants are of equal mass until fragmentation releases the reporter ions, which sequentially differ by
one mass unit. Reproduced from (63).
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Figure 1-4: Tandem mass spectrometry detection of iTRAQ tags. Because the iTRAQ reagents
are isobaric, the tagged protein appears as a single parent peak in MS. Upon fragmentation, the
multiplexed nature of the iTRAQ tags becomes evident as reporter ions separated by one mass unit.
Reproduced from (63).
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1.6 Detection and Monitoring of Cancer
Early detection of cancer is critical for improving the poor survival rates of cancer patients.
Unfortunately, current clinical technologies are deficient in their ability to detect early cancer
growth and to fully eradicate certain tumors after removal (40). Two of the most common
cancers in the United States, breast and prostate cancers, are particularly difficult to diagnose.
Common diagnostic tools, such as Magnetic Resonance Imaging (MRI), are not sensitive or
specific enough to identify early cancerous growth, especially when nonmalignant lesions are
also present. As most tumors are usually not detectable until they have reached a size of
approximately 1cm, by then they are more likely to have metastasized. Scientists have dealt with
these deficiencies by developing creative assays that allow for the early detection and targeting
of tumors.
Targeted approaches, such as monoclonal antibodies, are in development to better detect
cancer. Antibodies designed to detect tumor-associated antigens have been generated and are
capable of homing in on tumors and detecting angiogenesis mice and in clinical trials (49-53).
Noise and specificity issues pose major limitations, however, as significant antibody signal levels
in the tumor have been difficult to achieve over the background. Strategies to improve targeting
include using tumor-specific peptides (52), improved labeling techniques (54), enhancing tumor
vessel permeability for better extravasation (55), and upregulating the expression of tumor
antigens in vivo (56). Protease detection approaches have also been used with the goal of
increased sensitivity due to activity-based diagnosis. One study delivered near-infrared
fluorescence (NIRF) probes using a polymer scaffold that allowed for long circulating times and
improved delivery (57). After accumulation of the NIRF probes at the tumor site, protease
cleavage of the probes freed the fluorophores from their quenched state and a 12-fold increase in
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signal could be detected. Issues with specificity plague an activity-based approach, which could
be solved by probing the protease profile of the tumor using multiplexed probes.
Nanoparticle-based devices also have the potential to impact cancer treatment significantly
since accessing the local cancer environment within the body is key to early detection and better
treatment outcome (40). While most diagnostic tools and treatments ignore the local environment
and rather test the serum, these novel devices are able to precisely target cancer cells and thus
sense the local tumor environment. Treatments of various cancer types, such as epithelial ovarian
cancer, could highly benefit from the sensing of the local environment through the identification
of cancer-related biomolecules (43,44). While nanoparticles that can target tumors to improve
MRI imaging or deliver drugs are certainly possible solutions, more novel diagnostic schemes
and devices are needed to detect early signs of cancer. One such device uses nanoparticle
magnetic relaxation switches to monitor the beta subunit of human chorionic gonadotrophin
(hCG-p), a cancer biomarker (40). The device, implanted at sites where tumors have been
removed, allows MRI to detect changes in the magnetic relaxation time when the nanoparticles
cluster around hCG-p, thus allowing for the local monitoring of tumor reoccurrence.
Serum biomarker assays have also been proposed for cancer. Most clinically used biomarker
diagnostics lack the ability to detect small tumors and many biomarkers have low sensitivity and
specificity, such as CA-125 for ovarian cancer and PSA for prostate cancer. Panels of biomarkers
for diagnosing cancer would have much more potential for offering early detection that is
accurate across cohorts of patients. For most serum analytes, however, robust detection in plasma
is challenging since most biomarkers are shed from diseases tissues at low levels and are further
diluted in the blood. Better results could perhaps be achieved by probing the tumor environment
with panels of exogenous biomarkers that can efficiently be assessed in a non-invasive manner.
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Such an approach would avoid the problems with serum complexity and would provide more
accuracy due to the multiplexed assessment of the tumor environment.
1.7 Purpose of Inquiry
The use of 'synthetic biomarkers' that are designed to respond through specific mechanisms
to complex disease processes and report non-invasively through the urine is proposed in this
thesis. By using exogenous biomolecules as indicators of disease, the platform can be tailored to
respond to specific molecular processes and signals within the disease. Aberrant protease
activities are present in many complex disease processes, especially in cancer, thrombosis, and
liver fibrosis (14). Despite the importance of proteases in disease, few technologies exist for the
detection and multiplexed monitoring of aberrant protease activities in vivo. In this work, the
aberrant matrix metalloproteinase (MMP) activity present within cancer is focused on using
synthetic biomarkers consisting of long circulating peptide-nanoparticle probes designed to
intravenously home in on the disease site and profile enzyme activity by releasing mass reporters
locally upon proteolysis (Fig. 1-5). These cleaved mass-encoded reporters are designed to then
filter into the urine for identification by using liquid chromatography tandem mass spectrometry
(LC MS/MS). A description of how the administration of prodiagnostic reagents, through
quantified protease activities, can improve the low sensitivity and specificity associated with
current biomarker tests is presented in this thesis.
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Protease Massa substrate reporter
Peptide Nanoworm
Library (NW)
Synthetic Biomarker Library
Delivery to
disease sites
b p
Biomarker Proteolytic release of biomarkers
clearance to urine
C .^
urine coiection I ]
hv LC MS/MS quantification
of urinary biomarkers
Figure 1-5: Design Schematic. a) The 'synthetic biomarker' library conjugated to the surface of the
nanoworms is intravenously injected into mice. b) The nanoworms accumulate at the tumor site and
proteolytic cleave occurs. c) The mass-encoded biomarkers released by cleavage freely filter into the
urine and can be quantified by tandem mass spectrometry.
1.8 Goals
The idea of 'synthetic biomarkers' redefines the current state of biomarker tests by
allowing for the non-invasive administration of agents that profile local disease activity and,
through multiplexed reporting, provide signature of the underlying disease. The is aim to use the
nanoparticle-chaperoned synthetic biomarkers to detect and monitor cancer by measuring local
protease activities. Specifically, the goals of this study are:
1. To develop a set of nanoparticle-chaperoned reporters that proteolytically respond to a
panel of disease-relevant enzymes
2. To generate a multiplexed set of isobaric peptide reporters for quantification of protease
profiles in disease
3. To measure urinary fluorescence and mass signatures of in vivo protease activity in
animal models of cancer
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Chapter 2
Methodology
2.1 Peptide-nanoworm synthesis
Paramagnetic, dextran-coated iron-oxide nanoworms (NWs) with a longitudinal size of
~70nm were synthesized as previously described and derivatized with N-Succinimidyl
iodoacetate (SIA) and flurophore, Alexa Fluor 488 (41). The peptide-nanoworm library was
prepared from polyethylene glycol 20,000 (PEG) and the Glufib reporter peptides (95:20 mol
ratio) by SIA conjugation. The size and shapes of the NWs were analyzed by transmission
electron microscopy (TEM) and dynamic light scattering (DLS). Circulation half-life in the
blood was characterized in mice. NWs in PBS (5ptM FeO) were intravenously injected into nude
mice and blood was drawn at various times from the periorbital plexus using heparinized
capillary tubes (VWR). Blood samples were treated with 10mM EDTA (in PBS) to prevent
coagulation and centrifuged to pellet red blood cells. The samples were analyzed by fluorescence
using a fluorescence microplate reader (SpectraMax Gemini EM, Molecular Devices).
The Glufib reporter peptides were synthesized using Fmoc chemistry (Swanson
Biotechnology Center) and their composition was verified by mass spectrometry (Table 2.1).
Cysteine residues were added to the C-terminus of the peptides to allow for conjugation to the
nanoworms. The number of peptides or Alexa 647 dyes per NW was determined from the
absorbance spectrum.
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2.2 In vitro nanoworm protease activity assays
Forty-three Peptide substrates were screened for specificity to the MMPs (see Figure 2).
The substrates were synthesized and conjugated to NWs and these peptide NWs were screened
against recombinant MMP-2/8/9 (R&D Systems), MMP-7/14 (AnaSpec, Inc.), Thrombin, Tissue
Factor, Factor Xa, and Cathepsin B (Haematologic Technologies, Inc.). The substrates (2.5 pM)
were incubated with each of the recombinant enzymes (32nM) in a 96-well plate at 370 C. The
increased fluorescence due to proteolytic dequenching of the NWs was measured in 1 min
intervals for 3 h using a fluorescence microplate reader.
Ten peptide-NWs were selected from the screen for further experimentation (Table 2.1).
The 1O-plex NW library in PBS (100nm) was incubated with recombinant matrix
metalloproteinases (MMPs) and thrombin for 3.5 h at 37'C. The liberated Glufib reporters were
purified by centrifugation with a 10K MW-cutoff filter (Microcon, Millipore). After exposure to
UV-radiation (380nm) for 30 min, the purified reporters were dried in a speed vacuum
centrifuge. The proteolytic signatures were evaluated by analyzing the reporters using liquid
chromatography tandem mass spectrometry (LC-MS/MS).
2.3 In vivo imaging
Tumor-bearing (MDA-MB-435) NCR immuno-deficient mice (Charles Liver
Laboratories), aged 3-4 weeks, were injected with NWs loaded with Alexa Fluor 488 or peptides
derivatized with VivoTag-680. Bladder accumulation of the reporter peptides and tumor uptake
of the NWs were detected using an IVIS imaging system (Xenogen, USA).
For histological analysis, frozen sections of the tumors were prepared. The sections were
fixed with 4% paraformaldehyde. Tumor sections were stained for blood vessels (PCAM, Santa
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Cruz Biotechnologies) and nuclei (Hoechst). For pathological analysis and detection of NW
accumulation, the slices were mounted and imaged by fluorescence microscopy.
2.4 In situ zymography assays
In situ zymography was performed on fibrotic and tumor tissue sections on glass slides.
A mixture of 90ptL heated 0.5% agarose in PBS, 10pL peptide-NWs (1 mg/mL FeO), and 5pL of
20x Hoechst was applied to dried sections. After the slides were incubated at room temperature
over night, the proteolytic liberation of the peptide reporters was evaluated by florescence
microscopy.
2.5 Collection and purification of urinary peptides
Immuno-deficient mice were implanted bilaterally with MDA-MB-435 human melanoma
tumors and monitored for tumor progression. Fibrotic and tumor-bearing mice were
intravenously injected with the 10-plex peptide-NW library (5pM FeO) and background protease
inhibitor (Roche complete inhibitor, EDTA free). At 30 min post-injection for the tumor-bearing
mice and 2.5 h post-injection for the fibrotic mice, urine was collected for reporter readout. Each
cohort included 10 ~ 15 mice. Tumor-bearing mice were injected pre-tumor implantation and at
2 and 4 wk.
To prevent background proteolytic cleavage, collected urine samples were injected with
complete protease inhibitor (Roche). After exposing the urine to UV radiation (380nm) for 30
min to liberate the Glufib reporters, an aliquot of it was purified by using anti-FITC magnetic
beads (Dynabeads, Invitrogen) and total reporter fluorescence was measured using a
fluorescence microplate reader. Remaining urine was purified by TCA precipitation with 100%
(w/v) TCA. The Glufib reporters were extracted from the urine by filtration through a macro-
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spin column (The Nest Group, Inc.) at an elution fraction of 80% Acetonitrile/0. 1% Formic Acid
and further analyzed by LC-MS/MS.
2.6 LC MS/MS analysis
Purified urine samples were dried in a speed vacuum centrifuge, resuspended in a mixture
of 0.1% formic acid/5% acetonitrile, and analyzed by mass spectrometry (Swanson
biotechnology center, MIT). Peptides were isolated using a C18 nanoflow HPLC column (75
micron internal diameter Magic C18 AQ, Michrom BioResources, Inc.) at a flow rate of
300nL/min using a water/acetonitrile mixture with 0.1% formic acid. Analysis by MS was
performed using a QSTAR Elite Q-TOF mass spectrometer (AB Sciex).
2.7 Statistics
Euclidean clustering was performed on normalized y6 ion intensities in R. Class
prediction units of self-similarity (USS) k-nearest neighbor (k-NN) leave-one-out-cross
validation was performed using GenePattern software (Broad Institute of MIT-Harvard). The
Pearson's product-moment correlation coefficients between the different protease signatures
were determined using MATLAB. GraphPad 5.0 was used for the ANOVA analyses. SigmaPlot
was used for determining the Logistic regressions and ROC curves.
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Table 2.1. The iCORE peptide library. Peptide substrates are shown along with their associated mass
codes and the unique reporters that are generated for LC MS/MS quantification.
Probe[, b)
G1 e*3G*6VndneeGFfsAr-X-K(FAM)GGPQGIWGQC-NW
G2 e. 2 G**Vndnee*'GFfsAr-X-K(FAM)GGLVPRGSGC-NW
G3 e*1G*6Vndnee+2GFfsAr-X-K(FAM)GGPVGLIGC-NW
G4 eG+Vndnee+2GFfs*'Ar-X-K(FAM)GGPWGIWGQGC-NW
G5 eG*5VndneeGFfs*4Ar-X-K(FAM)GGPVPLSLVMC-NW
G6 e+3G+Vndnee*iGFfs+4Ar-X-K(FAM)GGPLGLRSWC-NW
G7 e*3GVndneeG*6FfsAr-X-K(FAM)GGPLGVRGKC-NW
G8 e+2GVndneeG+Ffs+Ar-X-K(FAM)GGf(Pip)RSGGGC-NW
G9 e* 1GVndnee+2 G+6FfsAr-X-K(FAM)GGfPRSGGGC-NW
G10 eGVndnee* 3G+6FfsAr-X-K(FAM)GGf(Pip)KSGGGC-NW
Substrate Isobaric mass codec dl
PQGIWGQ
LVPRGSG
PVGLIG
PWGIWGQG
PVPLSLVM
PLGLRSW
PLGVRGK
f(Pip)RSGGG
fPRSGGG
e*3G**VndneeGFfsAr
e+2G+Vndnee*1GFfsAr
e+G+Vndnee+2GFfsAr
eG**Vndnee+2GFfs*1Ar
eG+VndneeGFfs**Ar
e*3G* 1Vndnee*1GFfs*4Ar
e+3GVndneeG**FfsAr
e.2 GVndneeG**Ffs*'Ar
e*1GVndnee+2G**FfsAr
f(Pip)KSGGG eGVndnee*3G**FfsAr
y6 reporter [y6+H+]
GFfsAr
+'GFfsAr
+2GFfsAr
*
2GFfs*1Ar
GFfs**Ar
*
1GFfs+4Ar
G+FfsAr
G**Ffs*1Ar
+
2 G**FfsAr
683.4
684.4
685.4
686.4
687.4
688.4
689.4
690.4
691.4
*
3G+6FfsAr 692.4
A1X (3-amino-3-(2-nitrophenyl)propionic acid), FAM (carboxyfluorescein), Pip (pipecolic acid), NW (nanoworm)
bi lower case = d-amino acidi photocleaved C-terminus = CONH 2mass = 1589.8 Da
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Chapter 3
Results
3.1 Nanoparticle-conjugated fluorogenic 'synthetic biomarkers' proteolytically released into
urine
A set of biomarkers that can detect the protease profiles present in disease have been
designed. While this work is focused on biomarkers that detect the MMP family, which is
usually upregulated in cancer (15), also included are other enzymes commonly found in disease
such as the cathepsins, and in blood such as thrombin, Factor Xa, and Tissue Factor (TF). A
library of approximately 50 fluorescein-labeled peptides were created to cleave to the enzymes
of interest (16-20) and conjugated to iron-oxide nanoworm (NW) (21) nanoparticles. The iron-
oxide NWs were shown to have an average diameter of approximately 38nm and have a longer
half-life in vivo due to the surface-conjugated PEG (Fig. 3-1 a,b,c). To characterize the kinetic
cleavage of each peptide biomarker, the peptide-NWs were incubated with recombinant versions
of the MMPs, cathepsins, and blood enzymes. Proteolytic cleavage was measured by the
fluorescence increase associated with proteolytic liberation from the homoquenching of adjacent
fluorophores on NWs (Fig. 3-2). From each kinetic profile, the initial velocity of the enzyme
reaction was extracted and used to characterize each peptide biomarker (Fig. 3-3. From this
library of peptide substrates, 10 peptides associated with intense cleavage by the enzymes
implicated in cancer were chosen (Table 2.1).
With a set of 10 surface-conjugated peptide NWs, the ability of these peptides to
selectively clear into the urine after release from the NWs in a disease setting was then
investigated. For the disease setting, a MDA-MB-435 xenograft murine model of cancer was
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chosen. To investigate peptide trafficking, the peptide glutamate-fibrinopeptide B (Glu-fib,
EGVNDNEEGFFSAR) was conjugated to the peptide substrates to serve as a reporter for
proteolytic cleavage because Glu-fib is biologically inactive and has been found in urine after
coagulation, indicating its ability to pass renal filtration. While fluorogenically-labeled Glu-fib
intravenously (i.v.) injected into mice freely trafficked into the urine (Fig. 3-4a), the larger
nanoworms were unable to pass renal filtration and accumulated in the liver in a liver fibrosis
model with dysregulated MMP activity (Fig. 3-4b). The Glu-fib reporters were designed to be
able to pass the 2nm glomerular filtration limit, allowing the NWs to serve as a filter and only
permitting cleaved reporters to accumulate in the urine. The success of this design was
demonstrated with fluorogenically-labeled Glu-fib conjugated to the peptide substrates on the
NWs trafficking into the urine upon proteolytic cleavage in the disease setting, (Fig. 3-4c).
a b c
30
25
20
E 15
3 10
5
0A
__4 FI-Peptide + Alexa647 100
c onjugated NW
S--e- Unmodified NW 80
2 60
1.40
0
20
10 100 1000 400 500 600 700 800 0 2 4 6 8
Size (d. nm) Wavelength (nm) Time (hr)
Figure 3-1: Characterization of the iron-oxide nanoworm chaperones: a) Size distribution of the
nanoworms as demonstrated by dynamic light scattering. b) The absorbance spectrum of the nanoworms
conjugated to fluorogenic peptides (-500nm) +Alexa 647 (blue) and unmodified nanoworms (red). c)
Circulation time of the nanoworms conjugated to the peptide biomarkers with (blue) and without PEG
(red).
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Figure 3-2: Kinetics of proteolytic cleavage of peptide substrates. Peptide biomarkers designed to cleave
by proteolysis were conjugated to nanoworms and kinetics were determined by incubation with
recombinant proteases.
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Figure 3-3: Heatmap of the cleavage efficiency of all protease (left)-substrate (top) combinations
possible with the chosen library. Cleavage intensities were measured by taking the initial slope of the
cleavage kinetics profile (see Fig. 7).
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Figure 3-4: Designer biomarkers arrive at the site of disease and accumulate in the urine. a)
Unconjugated VivoTag-680-labeled peptide substrates freely clear into the urine as determined by in vivo
live animal imaging in both the cancer and control animals. b) Biomarker-free VivoTag-680-labeled
nanoworms are unable to pass the renal filter and accumulate in the urine in both fibrotic and control
animals. c) Nanoparticle-chaperoned peptide biomarkers are cleared into the urine only in cancer animals.
3.2 Multiplexed Protease Profiles in Disease using Mass Spectrometry
While fluorescence analysis of Glu-fib in the urine correlated with disease, this work
sought to multiplex the protease profile of disease using the 10 peptide-substrates. Glu-fib is
traditionally used as a standard in mass spectrometry because of its high ionization ability. When
the doubly charged Glu-fib species is subjected to collision induced dissociation (CID), it
fragments into b-type ions and y-type ions (Fig. 3-9a). In the MS spectrum, Glu-fib (MW:
1570.6) appears as a doubly charged parent ion peak (Fig. 3-5a), but upon fragmentation a
spectrum of y-type ions and b-type ions appear (Fig. 3-5b). As confirmed by MS/MS, Glu-fib
has numerous ion fragments with high signal-to-noise ratios, making it an appropriate choice as a
mass reporter because high sensitivity and quantification will be possible. To render Glu-fib
resistant to proteolytic activity, Glu-fib was synthesized using d-isomer amino acids and these
reporters were conjugated to the N-termini of our peptide substrates using a photo-labile linker
consisting of a nitrophenyl group (Fig. 3-6). A photolabile linker is integral to the reporting
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scheme because upon cleavage by a protease, the mass reporter is still conjugated to the
remaining cleaved substrate portion. Upon UV irradiation, the Glu-fib reporter is freed from the
cleaved substrate and is able to then be quantified by mass spectrometry. The scheme was
validated by exposing Glu-fib linked to a peptide substrate through the photolabile molecule
(compound I, Fig. 3-7a) to UV irradiation. After exposure to UV light, a doubly charged,
acetamide-terminated Glu-fib is generated from peptide cleavage at the linker group (compound
II, Fig. 3-7b). To test the robustness of the approach to use Glu-fib as mass reporters in animals,
the Glu-fib mass tags attached to NWs were injected into tumor-bearing animals and their urine
was collected after 2.5 hours. After the urine was irradiated to uncage the Glu-fib mass reporters,
LC MS/MS was performed on the isolated mass tags. The MS spectrum revealed multiple peaks,
but the Glu-fib parent peak was present with sufficient intensity and revealed that the Glu-fib
trafficked into the urine without degradation (Fig. 3-9a). Fragmentation of the Glu-fib tags
yielded a MS/MS spectrum with the expected y6 ions, demonstrating the feasibility of using Glu-
fib peptides as mass tags in vivo.
To develop Glu-fib into a system that could allow for the multiplexed detection of when
the 10 peptide-substrates (Table 2.1) are cleaved, isobaric mass tag technology was incorporated
(23,34). Glu-fib was encoded with heavy amino acids such that 10 variants of Glu-fib were
generated where each had a parent ion with identical mass, but were designed upon
fragmentation by tandem mass spectrometry to yield C-terminal y6 ions that were each 1 Da apart
in mass (Fig. 3-8a,b). Of all the C-terminal y-type ions, the y6 ions demonstrated the highest
signal and were thus chosen for the reporter ion. The mass-encoding technology was developed
around the y6 ion fragment (GFFSAR) by creating isotopic versions that incorporated heavy
amino acids, yielding a set of 10 Glu-fib reporters that each contained a y6 ion fragment of
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different mass (Fig. 3-10). For each Glu-fib fragment to have equal mass, the y6 ion was
balanced by the remainder of the Glu-fib peptide (EGVNDNEE). This allows each peptide-
substrate to be associated with a Glu-fib y6 ion of unique mass. This approach of creating mass
encoded multiplexed reporters was named "isobar Coded Reporters" (iCORE). This approach
was validated experimentally by creating an equimolar mixture of the 10-plex iCORE library
(Fig. 3-11) and subjecting it to tandem mass spectrometry. As expected, the entire library ionized
as a single parent peak (789.95 t 0.5 m/z, Fig. 3-10), but upon fragmentation, appeared as 10
single peaks corresponding to the individual mass encoded reporters (683.4-692.4 m/z, Fig. 3-
10). To confirm the ability of the peptide substrates to generate a signature upon proteolytic
cleavage, an equimolar mixture of the 10-plex iCORE library conjugated to the peptide
substrates via the photo-labile linker was incubated with recombinant MMP-9. The cleavage
products were isolated by size filtration and subjected to UV irradiation to release the photo-
caged Glu-fib reporters. Tandem mass spectrometry showed varying intensities of Glu-fib y6
ions, revealing a unique iCORE profile for MMP-9 activity (Fig. 3-12). Because naturally
occurring isotopes can make quantification difficult for the proteolytic signatures, a specific
fragmentation unit mass window was centered on the parent peak to prevent leakage of the
isotope peaks. This correction reduced the isotope peak in the MS/MS to approximately 5% of
the parent peak. By performing this necessary correction, quantification could then be
accomplished through the iCORE technology.
To experimentally demonstrate the potential for this approach, a mixture of 10-plex
reporters at defined ratios: 1:2:3:5:10:10:5:3:2:1 was created and could be visualized with the
correct ratios by LC MS/MS (Fig. 3-13a). With and without the naturally occurring isotope
correction, a linear correlation was observed between the ratios spiked in and the peak intensities
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measured (Fig. 3-13a,b). Despite the linear relationship in both cases, all future signatures were
corrected for naturally occurring isotopes.
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Figure 3-5: Fragmentation pattern of the Glu-fib peptide into y-type ions during LC MS/MS after
administration. a) The MS spectrum of Glu-fib showing the parent ion located at 785.8464 m/z. b) The
MS/MS spectrum of the fragmented Glu-fib parent peak. The y-type ions are shown. The amino-acid
sequence of Glu-fib is shown with the fragmentation positions for the y-type and b-type ions.
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Figure 3-6: The scheme used for connecting the Glu-fib reporter to the peptide-substrate through a
photolabile linker. To separate the mass reporter from the cleaved peptide-substrate after proteolysis, UV
light is used to cleave the photo-labile linker, uncaging the mass reporter for MS quantification.
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Figure 3-7: UV exposure uncages the mass reporter for MS identification. a) The molecular mechanism
for cleavage of the photolabile linker. The mass encoded Glu-fib reporter is attached to the peptide
substrate by a photolabile linker (compound I). UV irradiation of compound I activates peptide cleavage
and release of the Glu-fib reporter (compound II, red). b) Confirmation by LC MS/MS that the
photolabile linker frees the mass reporter conjugated to the cleaved peptide substrate (black, 881.7 m/z) to
yield the original mass reporter (red, 785.4 m/z).
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Figure 3-8: Isobaric Coded Reporter (iCORE) mass encoding scheme. A) The tandem mass
spectrometry spectrum after collision induced dissociation of Glu-fib. The observed intensities are the C-
terminal y6 ion fragment intensities. B) The Y6 ion fragment (red) is the basis for mass encoding 10
variants of Glu-fib that each differ by 1 mass unit. These variants were produced by incorporating heavy
amino acids in the y6 ion and then balancing this in the remaining portion such that each of the 10 variants
had equal mass.
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Figure 3-9: Fragmentation pattern of the Glu-fib peptide into y-type ions during LC MS/MS after
administration in vivo and retrieval through the urine. a) The amino-acid sequence of Glu-fib shown with
the fragmentation positions for the y-type and b-type ions. b) The MS spectrum of Glu-fib showing the
parent ion located at 785.3690 m/z. c) The MS/MS spectrum of the fragmented Glu-fib parent peak. The
y-type ions are shown.
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Figure 3-11: The MS/MS spectrum of the 10-plex synthetic biomarkers. The Glu-fib biomarkers
fragment into y-type ions with the Y6 fragments of interest. The parent peak is fragmented to yield
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Figure 3-12: The iCORE peptide library allows for multiplexed quantification of protease profiles using
liquid chromatography tandem mass spectrometry (LC MS/MS). A profile is shown of the 10-plex library
conjugated to nanoworms cleaved by recombinant MMP-9.
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Figure 3-13: Quantification of the 10-plex iCORE library signatures. a) MS/MS spectrum of a 10-plex
library mixture with the probes spike in the following intensities: 1:2:3:5:10:10:5:3:2:1. b) In both the
uncorrected and c) the corrected naturally occurring isotope case, the quantification of peak intensities
correlated well with the input ratios. (r2 = 0.99, n = 3, error = SEM).
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To demonstrate how iCORE could yield signatures for different enzymes, proteolytic
signatures using the 1 0-plex library were generated in vitro. The 10-plex probe library consisting
of photo-caged iCORE mass reporters conjugated to NWs were exposed in equimolar
concentrations to recombinant MMP-2, MMP-9, MMP-12, and Thrombin. After incubation, the
cleaved reporters were isolated by size filtration and subjected to UV-irradiation to free the
photo-caged iCORE mass tags. As expected, the substrate activities were correlated to distinct
iCORE signatures consisting of differing y6 ion intensities (Fig. 3-14a). The signatures for each
of the four proteases tested were not correlated in any way (Pearson's correlation analysis, Fig.
3-14b), signifying the potential for the iCORE system to characterize enzymes by mass tag
signatures. Because the substrates are designed to cleave to different proteases (Fig. 22), unique
signatures could be obtained by proteolysis and quantification by LC MS/MS. The uniqueness of
signatures is important because the presence of disease is detected by measuring the different
proteases expressed. If unique protease signatures were not possible to obtain using the iCORE
methodology, then it would be difficult to achieve accurate diagnosis by the platform.
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Figure 3-14: iCORE signatures for proteases. a) The 10-plex iCORE library was subjected to
recombinant proteases in vitro and the MS/MS spectra were generated. b) A heat map of the Pearson's
correlation coefficients between the protease signatures reveals the uniqueness of the iCORE signatures.
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3.3 Synthetic biomarkers for early and accurate detection of cancer
Early detection of cancer is critical for improving poor survival rates of cancer patients.
Most clinically used biomarker diagnostics lack the ability to detect small tumors and many
biomarkers have low sensitivity and specificity, such as CA- 125 for ovarian cancer and PSA for
prostate cancer. Many approaches are shifting to multiplexed analysis of biomarkers to overcome
these limitations (4). This work proposes that the 10-plex iCORE panel of 'synthetic biomarkers'
could provide the potential to profile proteases in cancer and lead to improved sensitivity and
specificity over current biomarkers for early detection of tumors.
For the disease model, melanoma (MDA-MB-435 cell line) tumor xenografts in athymic
nude mice were investigated. Because nanoparticles have been shown to passively accumulate at
the site of tumors due to the enhanced permeability and retention effect (22) (EPR), the NWs
serve as chaperones for delivery of the peptides to the disease site to allow for an amplified
signal and earlier detection. For our murine melanoma model, MDA-MB-435 xenografts were
established in the hind flanks and tumor progression was monitored at 0, 2, and 4 weeks by
injection of the 10-plex iCORE library NWs (Fig. 3-15a). While no significant levels of protease
activity were measured at 2 weeks by urine fluorescence of the reporters, levels of the reporters
in urine were significant at 4 weeks and these levels were correlated with tumor burden (p <
0.05; n = 10; Fig. 3-15b,c). The signal observed was confirmed to be due to NW accumulation at
the tumor site due to the enhanced permeability and retention (EPR) effect (Fig. 3-16). Urine
samples from the 0 and 4 week time points were further analyzed by mass spectrometry to
generate a 10-plex signature of the disease. LC MS/MS allows quantification of the signature
intensities from diseased and healthy animals using the iCORE platform (Fig. 3-17a). The
signatures generated from the mice were analyzed by unsupervised hierarchical clustering using
Euclidean distance (Fig. 3-17b). Unsupervised learning is a powerful tool because it is capable of
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organizing data into groups of members based on similar characteristics. The clustering
algorithm does not require any prior information, basing the grouping purely on observed
similarities between data members. In the analysis, distance between probe intensities as the
metric to group animals into diseased or healthy groups was used. Successful clustering of most
of the diseased and pre-disease animals into two different groups using four probes (G1 -G4) with
79% accuracy (n=19) was achieved. Visually it is clear that certain probes were cleaved more
(G4) than others (G1) in the disease state. It is clear that varied behavior of the probes is
indicative enough to classify diseased and control cohorts of animals correctly.
To further characterize the ability of these biomarker signatures to indicate disease, a
larger group of animals was tested (n=36). With this cohort of animals, diseased and control
groups were appropriately classified by unsupervised clustering (Fig. 3-18). The predictive
nature of the platform was tested for this cohort of animals using a k-nearest neighbor (KNN)
leave-one-out-cross-validation analysis (Fig. 3-19). The KNN algorithm bases classification of a
member on its n nearest neighbors. The algorithm observes locally a certain member and
classifies it to the majority trait of the nearest data members. Leave-one-out cross validation
trains the classifier by leave out a data point and using the rest of the data as a training set to
classify that one element left out. The process of training the data in such a manner yields a
higher accuracy and is used for iCORE approach. As the number of biomarkers classifiers used
in the KNN algorithm increased towards 4, the sensitivity and specificity of disease prediction
increased, with a maximal prediction of 92% (33/36 animals correctly classified as tumor or pre-
disease, sensitivity = 83%, specificity = 100%) at 4 probes (peptide substrates). Including more
than 4 biomarkers in the class prediction reduced sensitivity and specificity, indicating that non-
informative probes added noise to the data. An important aspect of the KNN algorithm is the
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usage of many neighbors to classify each data member. Testing a range of different neighbor size
for a 10-probe and 4-probe analysis (Fig. 3-20) showed that 3-nearest neighbors yielded the best
accuracy. The ability for multiplexed biomarkers, specifically 4 probes, to better predict disease
than single probes shows the promise of screening for 'synthetic biomarkers' that are able to
diagnose disease based on proteolytic cleavage.
To demonstrate the advantage of multiple probes for sensitivity and specificity, the
iCORE signatures were quantified by mass spectrometry and analyzed by receiver operating
characteristic (ROC) using risk score functions determined by logistic regressions for the
biomarkers. A logistic regression fits a binomial function to the biomarker data, providing a
predicted probability that an animal is diseased or healthy. These predictions can then be used to
generate a ROC curve, which is a graphical plot of sensitivity vs. specificity and indicates the
tradeoffs between the two characteristics. A ROC curve can be used as a standardized method for
evaluating the effectiveness of a diagnostic. Ideal tests will have specificity and sensitivity as
high as possible, which is signified by an ROC curve that follows the border along the upper left
corner. The predictive value of the diagnostic can be evaluated using the area under the curve
(AUC), which indicates the probability that the test will classify a diseased animal correctly..
The higher the AUC the more accurate the diagnostic is in predicting the state of the animal.
ROC curves were generated for each of the single biomarkers for the tumor-bearing animals
(Fig. 3-21) with the G4 (AUC= 0.76), G8 (AUC = 0.62), and G9 (AUC=0.64) single biomarkers
having the most predictive value. A ROC analysis of combinations of biomarkers showed that
double (GI + G4, AUC = 0.80) (Fig. 3-22) and triple combinations (G4+G1O+G6, AUC = 0.74)
(Fig. 3-23) had improved predictive performance over the single biomarkers. Not all the
combinations (Fig. 3-22,3-23) had improved AUC values. It is important to select the right
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combinations of biomarkers as some will only incorporate noise into the analysis and reduce the
accuracy of prediction. The ability for combinations of certain biomarkers to yield better
accuracy demonstrates the potential for multiplexed biomarkers to better diagnose disease.
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Figure 3-15: Administration of iCORE NW library to mice monitors disease progression. a) The scheme
of tumor implantation and iCORE NW injections. b) The trafficking of iCORE reporters into the urine in
the diseased animals. c) Correlation of the fluorogenic peptide biomarkers in the urine to the increasing
tumor burden over 4 weeks. Significant increase in reporter fluorescence at 4 weeks (p <0.05, ANOVA).
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Figure 3-16: Trafficking of the NWs into the tumor site. Fluorescent analysis of tumors removed from
mice injected with fluorescently-labeled NWs and saline control show that NWs traffic into the tumor
site. (left). Histological analysis of the tumor reveals that NWs (green) extravasate from the blood vessels
(red) and enter the tumor tissue.
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Figure 3-17: Unsupervised clustering of protease signatures enables identification of diseased vs. healthy
animals. Top: Heat map of proteolytic signatures of the iCORE library from tumor and control animals
quantified using LC MS/MS. Bottom: Training analysis by unsupervised clustering reveals that four
probes (G 1 -G4) best differentiate the tumor and control animals.
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Figure 3-18: Protease signatures accurately classify disease and non-disease groups. Unsupervised
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Figure 3-19: k-NN leave-one-out-cross-validation classifies disease vs. non-diseased animals. Accuracy,
sensitivity, and specificity are plotted vs. number of probes used.
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Figure 3-20: k-NN leave-one-out-cross-validation with the number of neighbors varied. top: Accuracy,
sensitivity, and specificity are plotted vs. the number of neighbors used in the analysis for 10 probes.
Bottom: Accuracy, sensitivity, and specificity are plotted vs. the number of neighbors used in the analysis
for 4 probes. In both situations, 3-nearest neighbor yields the best predictive results.
51
U i
I
a.U
I
G2, AUC = 0.51
c
U)
1.0-
0
.
6n
0.4-
0.2-
0.0
1 - Specificity
G4, AUC = 0.76
1.0-
0.8-
0.6-
0.4-
0.2-
0.2 0.4 0.6
I -Specificity
0.8 1.0 0.0
G5, AUC = 0.51
0.2 0.4 0.6
1 -Specificity
G6, AUC=0.56
Z
0.2 0.4 0.6
1- Specificity
0.8 1.0
1.0-
0.8-
0.6-
0.4-
0.2-
0.0
G7, AUC = 0.51
0.2 0.4 0.6
1 - Specificity
0.8
2:
1.0
1.0-
0.8-
0.6
0.4-
0.2-
(I n
0.0
G8, AUC = 0.62
0.2 0.4 0.6 0.8
1- Specificity
G9, AUC = 0.64
U)
0.2 0.4 0.6 0.8 1.0
1 - Specificity
1.0-
0.8-
0.6-
0.4-
0.2-
0.0 0.2
C
e
U)
1.0-
0.8-
0.6-
0.4-
0.2-
0.4 0.6 0.8 1.0
1 -Specificity
0.0 0.2 0.4 0.6 0.8 1.0
1 -Specificity
G10, AUC = 0.59
0.2 0.4 0.6 0.8 1.0
1 -Specificity
Figure 3-21: The ROC curves for each of the synthetic biomarkers with associated AUC value.
52
1.0-
0.8-
0.6-
0.4-
0.2-
2:
0.8 1.0
0.0
1.0-
0.8-
0.6-
0.4-
0.2-
C
a
U,
1.0
0.0
1.0-
0.8-
0.6-
0.4-
0.2-
U
0.0
__ UP.7r7-P-42
U'1 n 0.
r 70
G1, AUC=- 0 .53 G3, AUC = 0.57
G100G, AUC a 0AC0
04 i2 a4 0. *,1,I A s is 1'*
1 -$Po - p
GG, AUC "71 04+010. AUC -0.60
&@ 02 &4 1 S 100 2 04 6."05 IA
1-SpacIfcy I-SW"
Figure 3-22: The ROC curves for double combinations of the most predictive synthetic biomarkers with
associated AUC value.
53
G4+0 AUC a &.89
G4+G10+G3, AUC a 0.73
1.
0.0 0.2 0.4 G.A
1 -Specftity
1.0 *A 0.6
I - Spcy
G4+G10+G9, AUC = 0.70
1.0
I - Specncy
G4+G10+GS, AUC = 0.71
I -SPOCftty
Figure 3-23: The ROC curves for triple combinations of the most predictive synthetic biomarkers with
associated AUC value.
54
is
1.0
S
G4+G10+G6, AUC = 0,74
Chapter 4
Discussion
Because of the challenges associated with endogenous biomarkers that have limited the
reliability and ability for early detection of current diagnostics, a multiplexed library of
'synthetic biomarkers' that are able to traffic into the site of disease and report identifying
signatures was developed. The synthetic biomarkers are designed to cleave to disease-relevant
proteases, such as the MMPs, to allow for detection and monitoring of cancer. The goals of this
project are:
1. To develop a set of nanoparticle-chaperoned reporters that proteolytically respond to a
panel of disease-relevant enzymes
2. To generate a multiplexed set of isobaric peptide reporters for quantification of protease
profiles in disease
3. To measure urinary fluorescence and mass signatures of in vivo protease activity in
animal models of cancer
4.1 Development of Nanoparticle-Chaperoned Reporters
Iron oxide NWs were surface functionalized with 'synthetic biomarkers' designed to be
cleaved in vivo using the relevant proteases and to release reporters that could be detected
fluorogenically in the urine and by identifying signatures using mass spectrometry. The NWs are
optimal delivery vehicles because they serve a bi-functional purpose: to increase the circulation
time for the synthetic biomarkers and to accumulate at the site of disease allowing for proper
proteolysis. Because the NWs naturally extravasate into tumors due to the enhanced permeability
and retention (EPR) effect, they are a natural choice for diagnosing cancer. Additionally, the
55
NWs only permit cleaved reporters to clear into the urine because of the 2nm glomerular
filtration limit, which prevents the larger NWs from passing through and hinders any uncleaved
reporters from being detected. The synthetic biomarkers were chosen by screening through a set
of 50 peptide substrates against a panel of recombinant proteases, which included MMPs and
clotting cascade enzymes such as thrombin. From this in vitro screen, a set of 10 peptide
substrates that represented cleavage by the MMPs and serum proteases were chosen to comprise
a 10-plex biomarker library. These peptide substrates were then conjugated through a photo-
labile linker to a fluorogenic Glu-fib, the mass reporter chosen due to its efficient renal clearance
and high ionization efficiency. When Glu-fib is subjected to collision induced disassociation
(CID) during LC MS/MS, the Glu-fib fragments into C-terminal y6 ions. By mass encoding these
ions, a 10-plex set of mass encoded reporters can be developed to detect cleavage of specific
peptide substrates.
4.2 Designing Reporters for Multiplexed Profiling of Proteases
With a set of peptide substrates for MMPs and other serum proteases, a reporting scheme
needed to be designed for the multiplexed detection of substrate proteolysis. While the ability to
detect significant urinary bulk fluorescence of these reporters in the diseased versus the control
animals was demonstrated, a multiplexed detection scheme was still needed to more accurately
diagnose and monitor cancer stages. A mass-encoding scheme was developed around the y6 ion
fragment (EGFFSAR) because of its high ionization and signal in LC MS/MS. A 10-plex set of
mass encoded reporters was designed by incorporating heavy amino acids in the y6 ion fragment,
such that each variant differed by one mass unit. The leftover fragment (EGVNDNEE) also
incorporated heavy amino acids to balance the weight of the y6 ion so that each parent fragment
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had the same mass and would elute at the same retention point along the extracted ion
chromatograph. This scheme allows for a 10-plex signature to be quantified in tandem mass
spectrometry which presents an improvement over current protease activity detection
technologies. Many of the current activity based probes for profiling proteases utilize
fluorescence as the readout mechanism (31). These technologies have been successful at
detecting diseases, such as coronary artery disease and tumors (45,46). Using fluorescence as the
readout for multiplexing protease activities is quite restricted due to the small number of
fluorophores that could be potentially used due to spectral overlap considerations. Thus,
combining a fluorogenic approach with a highly multiplexed mass-encoding scheme allows for
high-throughput fluorescence analysis of the urine with expanded resolution of disease
signatures through mass spectrometry.
4.3 Early and Accurate Detection of Colorectal Cancer
Furthermore, these findings are extended to address the challenge of detecting tumors at
early stages (< 1 cm3) and the limited detection capabilities of endogenous biomarkers. It can be
possible for certain tumors to grow for a decade to size > 2.5cm before shedding detectable
levels of biomarkers. For current biomarker-based diagnostics to be effective, they will need to
have drastically improved sensitivity so tumors can be detected at earlier stages before metastasis
is possible.
With this 10-plex iCORE library, success was achieved in differentiating melanoma
xenograft-bearing mice from the control ones using unsupervised clustering of the 10-plex
signatures. By using the k-NN leave-one-out-cross-validation technique, the biomarkers could be
evaluated for their role in predicting early stages of disease. Notably, the best results were
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achieved by classifying based on the three nearest neighbors and with four biomarkers, which
yielded a prediction rate of 92%. When more biomarkers were included, the predictive value of
the signatures was reduced, indicating that the remaining biomarkers introduced higher levels of
noise.
Additionally, the diagnostic was evaluated in terms of ROC curves for analyzing the
specificity and sensitivity of the iCORE platform. While a few single biomarkers had predictive
success, combinations of double and triple biomarkers had even higher accuracy, indicating the
need for multiplexed diagnostic technologies. It is important to have multiple biomarkers for
profiling the range of proteases present in disease because of their marked variation and
promiscuity.
Because of the platform's basis on dysregulated enzyme activities and on a powerful
nanoscale delivery vehicle, the iCORE diagnostic can be tailored for many diseases and
applications. Many diseases have aberrant protease levels such as liver fibrosis and thrombosis.
Liver fibrosis is in fact a disease that could benefit the most from a synthetic biomarker
diagnostic because the standard diagnostic procedure is the biopsy. The iCORE platform offers
the ability to noninvasively diagnose the disease and even monitor progression and response to
therapy. Additionally, the ability to detect smaller tumors at remote sites suggests that our
diagnostic can be used for sampling small unknown disease sites that are unreachable with
current diagnostics, such as liver metastasis.
Furthermore, the iCORE scheme could be a mechanism for discovering novel
biomarkers, allowing for an expanded panel of 'synthetic biomarkers'. The iCORE diagnostic
platform is readily expandable to 100s of probes for the detection of nuanced diseases, such as
hepatocellular carcinoma, which is difficult to detect, and for extension to other diseases, such as
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liver fibrosis and thrombosis, because of its reliance on fundamental proteolytic mechanisms.
While the NWs used in this study are tailored for cancer diseases because of their natural
extravasation from vessels into these disease sites, extensive literature exists for designing
nanomaterials that target cargo to different tissues and organs (47,48). Being able to actively
target nanomaterials carrying the 'synthetic biomarkers' to any disease site will allow for this
platform to extend to a multitude of enzyme-regulated diseases.
The iCORE diagnostic platform also has the potential to simultaneously detect multiple
diseases at the same site. Patients with liver fibrosis or cirrhosis have a high likelihood for
developing hepatocellular carcinoma. Because of the multiplexed signatures this diagnostic
provides, it may be possible to differentiate a state in which the patient has both diseases.
Additionally, larger libraries would allow for mathematical deconvolution of the signatures to
identify the precise proteases present in the disease, which would overcome the challenges of
screening for substrates that are specific for certain proteases and are not promiscuous.
4.4 Conclusions
Nanotechnology has been leveraged to create a multiplexed set of 'synthetic biomarkers'
capable of profiling proteases at local tumor sites and to report non-invasively through the urine
for signature quantification by mass spectrometry. The platform was designed to home in to the
disease site to allow for increased sensitivity and to release isobaric mass reporters for
multiplexed quantification. An analysis of the diagnostic accuracy reveals that combinations of
the synthetic biomarkers yield better predictions than individual ones, emphasizing the need to
multiplex protease activity for successful diagnosis. This work is a motivation for further
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investigation to develop designer biomarkers that probe biological processes for diagnosing
underlying disease states.
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